Printed From BioPortfolio.com
[Comment] Secondary prevention shifts into second gear
18:31 EST 10 Nov 2017 | The Lancet
Aspirin has been a mainstay in the secondary prevention of cardiovascular events since the 1990s.1 In the mid-1990s, the antiplatelet clopidogrel was tested against aspirin in patients with atherosclerotic vascular disease and was found to reduce vascular death, ischaemic stroke, and myocardial infarction by 8·7%.2 The combination of clopidogrel and aspirin for secondary prevention to reduce cardiovascular events was tested in patients with symptomatic atherothrombosis; however, no benefit was observed.
Original Article: [Comment] Secondary prevention shifts into second gear
